255 related articles for article (PubMed ID: 31127314)
21. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
22. Relationships between vitreous levels of soluble receptor for advanced glycation end products (sRAGE) and renal function in patients with diabetic retinopathy.
Katagiri M; Shoji J; Kato S; Kitano S; Uchigata Y
Int Ophthalmol; 2017 Dec; 37(6):1247-1255. PubMed ID: 27830398
[TBL] [Abstract][Full Text] [Related]
23. Depression Is Associated With Progression of Diabetic Nephropathy in Type 1 Diabetes.
Ahola AJ; Harjutsalo V; Forsblom C; Pouwer F; Groop PH;
Diabetes Care; 2021 Jan; 44(1):174-180. PubMed ID: 33177173
[TBL] [Abstract][Full Text] [Related]
24. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.
Humpert PM; Djuric Z; Kopf S; Rudofsky G; Morcos M; Nawroth PP; Bierhaus A
Cardiovasc Diabetol; 2007 Mar; 6():9. PubMed ID: 17343760
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus.
Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
Diabetologia; 2018 May; 61(5):1212-1219. PubMed ID: 29417184
[TBL] [Abstract][Full Text] [Related]
26. Biomarker panels associated with progression of renal disease in type 1 diabetes.
Colombo M; Valo E; McGurnaghan SJ; Sandholm N; Blackbourn LAK; Dalton RN; Dunger D; Groop PH; McKeigue PM; Forsblom C; Colhoun HM;
Diabetologia; 2019 Sep; 62(9):1616-1627. PubMed ID: 31222504
[TBL] [Abstract][Full Text] [Related]
27. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
28. Haptoglobin genotype and renal function decline in type 1 diabetes.
Costacou T; Ferrell RE; Ellis D; Orchard TJ
Diabetes; 2009 Dec; 58(12):2904-9. PubMed ID: 19720796
[TBL] [Abstract][Full Text] [Related]
29. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
30. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).
Thorn LM; Forsblom C; Fagerudd J; Thomas MC; Pettersson-Fernholm K; Saraheimo M; Wadén J; Rönnback M; Rosengård-Bärlund M; Björkesten CG; Taskinen MR; Groop PH;
Diabetes Care; 2005 Aug; 28(8):2019-24. PubMed ID: 16043748
[TBL] [Abstract][Full Text] [Related]
31. Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes.
Panduru NM; Forsblom C; Saraheimo M; Thorn LM; Gordin D; Elonen N; Harjusalo V; Bierhaus A; Humpert PM; Groop PH;
Diabetologia; 2017 Sep; 60(9):1782-1790. PubMed ID: 28601908
[TBL] [Abstract][Full Text] [Related]
32. Divergent Changes in Plasma AGEs and sRAGE Isoforms Following an Overnight Fast in T1DM.
Miranda ER; Fuller KNZ; Perkins RK; Beisswenger PJ; Farabi SS; Quinn L; Haus JM
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781793
[TBL] [Abstract][Full Text] [Related]
33. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
Harjutsalo V; Thomas MC; Forsblom C; Groop PH;
Diabetes Obes Metab; 2018 Dec; 20(12):2759-2767. PubMed ID: 29962015
[TBL] [Abstract][Full Text] [Related]
34. Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.
Coughlan MT; Patel SK; Jerums G; Penfold SA; Nguyen TV; Sourris KC; Panagiotopoulos S; Srivastava PM; Cooper ME; Burrell LM; Macisaac RJ; Forbes JM
Am J Nephrol; 2011; 34(4):347-55. PubMed ID: 21876347
[TBL] [Abstract][Full Text] [Related]
35. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
Galsgaard J; Persson F; Hansen TW; Jorsal A; Tarnow L; Parving HH; Rossing P
Kidney Int; 2017 Nov; 92(5):1242-1248. PubMed ID: 28712855
[TBL] [Abstract][Full Text] [Related]
36. The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood.
Giannini C; D'Adamo E; de Giorgis T; Chiavaroli V; Verrotti A; Chiarelli F; Mohn A
Pediatr Nephrol; 2012 Feb; 27(2):269-75. PubMed ID: 21870072
[TBL] [Abstract][Full Text] [Related]
37. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
38. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
Steinke JM; Mauer M;
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
[TBL] [Abstract][Full Text] [Related]
39. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients.
Halimi JM
Diabetes Metab; 2012 Oct; 38(4):291-7. PubMed ID: 22622176
[TBL] [Abstract][Full Text] [Related]
40. Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus.
Marshall SM
Adv Chronic Kidney Dis; 2014 May; 21(3):267-72. PubMed ID: 24780454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
